title: EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis.
abstract: Clinical practice guidelines for pancreatic cancer based on evidence-based medicine (2006) were published by the Japan Pancreas Society (Committee for revision of clinical guidelines for pancreatic cancer) in March 2009 in Japanese, revised to Clinical Practice Guidelines for Pancreatic Cancer based on evidence-based medicine (2009) in July 2009 in Japanese and further revised to Clinical Practice Guidelines for Pancreatic Cancer (2013) in October 2013 in Japanese. These guidelines were established according to evidence-based medicine. A total of 629 papers were collected from among 4612 reports concerning pancreatic cancer listed in PubMed and Igakuchuo Zasshi between May 2007 and January 2011. This new set of guidelines was written by members of the Committee for the Revision of Clinical Practice Guidelines for Pancreatic Cancer in the Japan Pancreas Society. The guidelines provide an algorithm for the diagnosis (Fig. 1) and treatment (Fig. 2) of pancreatic cancer and address six subjects (Diagnosis, Surgery, Adjuvant therapy, Radiation therapy, Chemotherapy and stent therapy), with 35 clinical questions and 57 recommendations.
authors.affiliation: Department of Advanced Treatment of Pancreatic Diseases, School of Medicine, University of Occupational and Environmental Health, Kitakyushu yamaguch@med.uoeh-u.ac.jp.
authors.forename: Koji
authors.initials: K
authors.lastname: Yamaguchi
authors.affiliation: Hepatobiliary and Pancreatic Oncology Division, National Cancer Center, Tokyo.
authors.forename: Takuji
authors.initials: T
authors.lastname: Okusaka
authors.affiliation: Department of Gastroenterology, Tokyo Women's Medical University, Tokyo.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Shimizu
authors.affiliation: Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, Tokyo.
authors.forename: Junji
authors.initials: J
authors.lastname: Furuse
authors.affiliation: Department of Radiation Oncology, National Cancer Center, Tokyo.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ito
authors.affiliation: Department of Gastroenterology, JA Onomichi General Hospital, Onomichi.
authors.forename: Keiji
authors.initials: K
authors.lastname: Hanada
authors.affiliation: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Tooru
authors.initials: T
authors.lastname: Shimosegawa
mesh_terms: D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002760:Cholangiopancreatography, Endoscopic Retrograde; D003131:Combined Modality Therapy; D004322:Drainage; D019317:Evidence-Based Medicine; D006801:Humans; D060828:Induction Chemotherapy; D007564:Japan; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D010180:Pancreatectomy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D015607:Stents
keywords: EBM-based guidelines; pancreatic cancer